KR20170102887A - 브루톤 티로신 키나제 저해제의 합성 - Google Patents

브루톤 티로신 키나제 저해제의 합성 Download PDF

Info

Publication number
KR20170102887A
KR20170102887A KR1020177019206A KR20177019206A KR20170102887A KR 20170102887 A KR20170102887 A KR 20170102887A KR 1020177019206 A KR1020177019206 A KR 1020177019206A KR 20177019206 A KR20177019206 A KR 20177019206A KR 20170102887 A KR20170102887 A KR 20170102887A
Authority
KR
South Korea
Prior art keywords
compound
formula
ibrutinib
pyrazolo
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177019206A
Other languages
English (en)
Korean (ko)
Inventor
시릴 벤하임
웨이 첸
에릭 골드만
안드라스 호르바트
필립 피에
마크 에스 스미스
에릭 제이 베르너
Original Assignee
파마싸이클릭스 엘엘씨
잔센파마슈티카엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파마싸이클릭스 엘엘씨, 잔센파마슈티카엔.브이. filed Critical 파마싸이클릭스 엘엘씨
Publication of KR20170102887A publication Critical patent/KR20170102887A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020177019206A 2015-01-14 2016-01-14 브루톤 티로신 키나제 저해제의 합성 Ceased KR20170102887A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562103507P 2015-01-14 2015-01-14
US62/103,507 2015-01-14
PCT/US2016/013424 WO2016115356A1 (en) 2015-01-14 2016-01-14 Synthesis of a bruton's tyrosine kinase inhibitor

Publications (1)

Publication Number Publication Date
KR20170102887A true KR20170102887A (ko) 2017-09-12

Family

ID=56406389

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177019206A Ceased KR20170102887A (ko) 2015-01-14 2016-01-14 브루톤 티로신 키나제 저해제의 합성

Country Status (16)

Country Link
US (6) US20180009814A1 (enExample)
EP (1) EP3245208A4 (enExample)
JP (2) JP2018502077A (enExample)
KR (1) KR20170102887A (enExample)
CN (2) CN107108640A (enExample)
AU (2) AU2016206693A1 (enExample)
BR (1) BR112017015206B1 (enExample)
CA (2) CA2971460C (enExample)
HK (1) HK1246293A1 (enExample)
IL (4) IL322449A (enExample)
MA (1) MA41350A (enExample)
MX (2) MX366827B (enExample)
RU (1) RU2017128308A (enExample)
SG (2) SG11201705678YA (enExample)
WO (1) WO2016115356A1 (enExample)
ZA (1) ZA201704338B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210080468A (ko) * 2018-10-22 2021-06-30 화이자 인코포레이티드 피롤로[2,3-d]피리미딘 토실레이트 염, 이의 결정질 형태, 이의 제조 방법 및 이에 대한 중간체

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016127915A1 (zh) * 2015-02-12 2016-08-18 上海度德医药科技有限公司 伊布替尼的制备方法
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
KR102793563B1 (ko) 2016-03-04 2025-04-11 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
CN109206426B (zh) * 2017-07-06 2021-10-08 上海复星星泰医药科技有限公司 吡唑并嘧啶类化合物的制备方法
JP7166331B2 (ja) 2017-08-01 2022-11-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 中間体化合物及び方法
CN107814804A (zh) * 2017-10-27 2018-03-20 广州科锐特生物科技有限公司 依鲁替尼的制备方法
EP4353222A1 (en) 2018-03-19 2024-04-17 Taiho Pharmaceutical Co., Ltd. Use of sodium alkyl sulfate
EP3787751A1 (en) 2018-05-03 2021-03-10 Juno Therapeutics, Inc. Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
KR102742083B1 (ko) 2018-11-09 2024-12-16 다이호야쿠힌고교 가부시키가이샤 디메톡시벤젠 화합물의 제조 방법
CN109988175A (zh) * 2019-04-28 2019-07-09 梯尔希（南京）药物研发有限公司 一种依鲁替尼-d5的制备方法
EP3972977A1 (en) * 2019-05-21 2022-03-30 Janssen Pharmaceutica NV Processes and intermediates for preparing a btk inhibitor
US12459948B2 (en) 2019-05-21 2025-11-04 Janssen Pharmaceutica Nv Processes and intermediates for preparing a Btk inhibitor
EP4281454B1 (en) 2021-01-21 2025-03-05 Synthon B.V. Process for making ibrutinib
CN114853662B (zh) * 2021-02-05 2024-01-12 四川青木制药有限公司 手性肼基哌啶衍生物的制备方法
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023242384A1 (en) 2022-06-17 2023-12-21 Krka, D.D., Novo Mesto Crystalline form of ibrutinib

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550214A (en) * 1981-01-05 1985-10-29 Polaroid Corporation Blocked vinyl biphenyl compounds
US4874822A (en) * 1988-04-07 1989-10-17 Minnesota Mining And Manufacturing Company Process for the acrylamidoacylation of alcohols
MXPA06007326A (es) * 2003-12-23 2007-01-26 Astex Therapeutics Ltd Derivados de pirazol como moduladores de proteina cinasa.
DK2529622T3 (en) * 2006-09-22 2018-05-07 Pharmacyclics Llc INHIBITORS OF BRUTON-TYROSINKINASE
NZ579911A (en) * 2007-03-28 2012-05-25 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
US7718662B1 (en) * 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
EP2882751B1 (en) * 2012-07-30 2018-06-27 Concert Pharmaceuticals Inc. Deuterated ibrutinib
CN103121999A (zh) * 2012-08-29 2013-05-29 苏州迪飞医药科技有限公司 一种酪氨酸激酶抑制剂pci-32765的合成方法
US9156847B2 (en) * 2013-03-15 2015-10-13 Janssen Pharmaceutica Nv Processes and intermediates for preparing a medicament
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
CN103626774B (zh) * 2013-11-20 2015-11-04 苏州明锐医药科技有限公司 伊鲁替尼的制备方法
CN105471823B (zh) * 2014-09-03 2018-10-26 阿里巴巴集团控股有限公司 一种敏感信息处理方法、装置、服务器及安全判定系统
EP3248979B1 (en) * 2015-01-21 2021-04-14 Hefei Institutes of Physical Science, Chinese Academy of Sciences Novel inhibitor of flt3 kinase and use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210080468A (ko) * 2018-10-22 2021-06-30 화이자 인코포레이티드 피롤로[2,3-d]피리미딘 토실레이트 염, 이의 결정질 형태, 이의 제조 방법 및 이에 대한 중간체

Also Published As

Publication number Publication date
MA41350A (fr) 2017-11-21
SG11201705678YA (en) 2017-08-30
CN107108640A (zh) 2017-08-29
US20220098200A1 (en) 2022-03-31
AU2016206693A1 (en) 2017-07-13
IL322449A (en) 2025-09-01
WO2016115356A1 (en) 2016-07-21
JP2021035947A (ja) 2021-03-04
JP2018502077A (ja) 2018-01-25
US20250197404A1 (en) 2025-06-19
US20240158400A1 (en) 2024-05-16
IL253020A0 (en) 2017-08-31
MX394327B (es) 2025-03-24
EP3245208A1 (en) 2017-11-22
US20200347064A1 (en) 2020-11-05
HK1246293A1 (zh) 2018-09-07
IL274716A (en) 2020-07-30
MX2017009154A (es) 2017-10-12
RU2017128308A3 (enExample) 2019-10-24
CA2971460A1 (en) 2016-07-21
SG10201906517VA (en) 2019-08-27
US20180009814A1 (en) 2018-01-11
MX2019008815A (es) 2019-09-26
US20190367518A1 (en) 2019-12-05
CA2971460C (en) 2023-10-10
RU2017128308A (ru) 2019-02-14
AU2020230323A1 (en) 2020-10-01
CN113816962A (zh) 2021-12-21
IL308276A (en) 2024-01-01
BR112017015206B1 (pt) 2023-04-11
ZA201704338B (en) 2023-10-25
MX366827B (es) 2019-07-25
CA3210320A1 (en) 2016-07-21
BR112017015206A2 (pt) 2018-06-19
EP3245208A4 (en) 2018-10-17

Similar Documents

Publication Publication Date Title
KR20170102887A (ko) 브루톤 티로신 키나제 저해제의 합성
JP6133931B2 (ja) メチル｛４，６−ジアミノ−２−［１−（２−フルオロベンジル）−１Ｈ−ピラゾロ［３，４−ｂ］ピリジン−３−イル］ピリミジン−５−イル｝メチルカルバメートの調製方法および医薬上活性な化合物として用いるためのその精製方法
EP3215493B1 (en) Synthesis of copanlisib and its dihydrochloride salt
TW201825491A (zh) 製備細胞凋亡誘導劑的方法
KR20190018021A (ko) 치환된 5-플루오로-1h-피라졸로피리딘의 제조 방법
EP3848361B1 (en) Method of producing tetracyclic compound
KR102477924B1 (ko) 인돌 카르복스아미드 화합물을 제조하는 방법
KR20150114471A (ko) 살선충성 설폰아미드의 제조 방법
KR20160118359A (ko) 2-(아미노 에틸옥시) 벤조산 유도체의 고리화에 의한 3,4-디히드로-1,4-벤족사제핀-5(2h)-온 유도체의 제조
AU2009298757B2 (en) Thiazolyl-pyrazolopyrimidine compounds as synthetic intermediates and related synthetic processes
KR20090116753A (ko) 3-메틸-4-페닐이속사졸로〔3,4-ｄ〕피리다진-7(6Ｈ)-온의 신규한 제조 방법
WO2016071382A1 (en) Synthesis of pi3k inhibitor and salts thereof
AU2022269229B2 (en) Process for preparing btk inhibitors
KR20200092945A (ko) 레날리도마이드의 결정형
JP4596804B2 (ja) シラザプリルの製造方法
BR122022026564B1 (pt) Processos para a preparação de 1-((r)-3-(4-amino-3-(4-fenoxifenil)-1hpirazol[3,4-d]pirimidin-1-il)piperidin-1-il)prop-2-en-1-ona (ibrutinibe) e compostos
TW202134242A (zh) 用於生產式(i)之方法及中間體
WO2022032644A1 (zh) 一种取代的咪唑并[1,2-a]吡啶-2-基酰胺化合物的制备方法及其中间体

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170711

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210113

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230202

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20231123

Patent event code: PE09021S02D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240610

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20231123

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20230202

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20241108

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2024101002377

Request date: 20241108